论文部分内容阅读
目的前瞻性探讨枸橼酸莫沙比利分散片(新络纳)对美施康定治疗癌痛导致便秘的预防作用。方法 60例重度癌痛患者接受美施康定止痛治疗,随机分为治疗组和对照组各30例,治疗组在接受美施康定止痛治疗同时给予新络纳片,5㎎/次,3次/d,餐前15～30 min口服。详细观察两组便秘发生情况,并对症处理。结果便秘发生率治疗组为13.3%(4/30),对照组为73.3%(22/30),两组对比,统计学处理有显著差异(P<0.01)。结论新络纳对美施康定治疗癌痛导致的便秘有明显的干预作用。
Objective To prospectively investigate the preventive effect of mosapride citrate dispersible tablets (Xinnao) on the treatment of cancer pain caused by mexitumidine. Methods Sixty patients with severe cancer pain were treated with painkillers and were randomly divided into treatment group (30 cases) and control group (30 cases). The patients in treatment group were treated with melatonin for 5 days, d, 15 ~ 30 min before meals orally. Observed in detail the occurrence of two groups of constipation, and symptomatic treatment. Results The incidence of constipation was 13.3% (4/30) in the treatment group and 73.3% (22/30) in the control group. There was significant difference between the two groups in statistics (P <0.01). Conclusion The new entrainer has a significant intervention effect on the constipation caused by the treatment of cancer pain.